Videos

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Dr. Hope S. Rugo from UCSF Cancer Center on the Future of Angiogenesis in Breast Cancer

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment

Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors

Dr. J. Michael Dixon from the University of Edinburgh on Advances in Breast Cancer Axillary Node Procedures

Detecting breast cancer using mammography and self-examination was affirmed in a study that sharply contrasts the controversial 2009 USPSTF recommendations.

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors

A new set of statistical models will soon be available to help predict the risk of lymphedema for patients with breast cancer who have undergone ALND.

Women age 40 and younger with breast cancer experience similar outcomes in local recurrence and survival rates whether they undergo BCT or a mastectomy.

Dr. J. Michael Dixon from the University of Edinburgh Discusses Advances in Breast Cancer Treatment

Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67

The 2 upcoming conferences include the 7th Annual Multidisciplinary Symposium on Head and Neck Cancer and the School of Breast Oncology.

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Biomarkers

Early detection offers the best chance for a cure.

Dr. Matthew J. Ellis from Washington University Discusses the Future of the PI3-Kinase Pathway

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Flaxseed had no effect on reducing hot flashes in postmenopausal women who reported experiencing 28 or more hot flashes per week.

Dr. Debu Tripathy from USC Norris Cancer Center on Determining the Best HER2 Targeted Therapy

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67

It's hard to tell which moves more quickly: Edith Perez's feet, or her mind.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Dr. Joyce O'Shaughnessy from Baylor Sammons Cancer Center on Negative TNBC Iniparib Trial Results

In postmenopausal diabetic women, metformin use was associated with lower ER and PR breast cancer incidence.

Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies

Patients with breast cancer who undertook yoga following radiotherapy derived physical and emotional benefi ts from the ancient Indian practice, according to research presented at ASCO.

Dr. Mary J. C. Hendrix from Northwestern University's Feinberg School of Medicine on Metastatic Tumor Cells in Microenvironments

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Breast cancer survivors who stop working during chemotherapy may face the loss of long-term employment for several years after their diagnosis.

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Avastin as Her Standard of Care